Preparing your Praveta Brief...
Based on official legislative actions published by Congress.
Referred to the Committee on Armed Services, and in addition to the Committee on Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This timeline shows the bill's position in the federal legislative process based on official congressional actions.
Referred to the Committee on Armed Services, and in addition to the Committee on Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Praveta hasn't published a community poll for this bill yet. If one becomes available, you'll be able to participate and see results here.
Praveta uses official congressional material as its source of truth. You can review the underlying record directly.
The bill would make the Defense Department create a strategy to address biotechnology threats from foreign adversaries, especially China.
Introduced in the House on October 22, 2026
Would require a DoD strategy integrated into defense planning
Directs an intelligence assessment of China’s military biotechnology use
Would create an interagency Biotechnology Risk Contact Group
If enacted, the bill would formalize defense planning around biotechnology risks, prompt new government reports and interagency monitoring, and focus oversight on foreign biotech investments.
The Department of Defense, intelligence agencies, other federal agencies, and foreign-investing biotechnology entities would be affected.
Introduced in the House on October 22, 2026, and referred to the Committee on Armed Services and the Permanent Select Committee on Intelligence for consideration.
Praveta summarizes official congressional material and keeps the underlying source available for review.